IP : IXICO plc - AGM statement and board changes​

Building scale and momentum with commercially-led growth strategy

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, will hold its Annual General Meeting at 9.30am today at the offices of FTI Consulting LLP, 200 Aldersgate, London, EC1A 4HD.

At the meeting Charles Spicer, the Company's Chairman will make the following statement:

'The year ended 30 September 2017 was a year of change for the Company, with a renewed focus on our biopharmaceutical customers. I am pleased to report a strong performance with increased revenue and reduced operating losses. We ended the year by announcing two new contracts in Huntington's disease, closely followed by our first two wearable biosensor contracts. These four contracts have a combined value of c. £3m and, together with our existing contracted revenues, represent a firm foundation from which we plan to execute our commercially-led growth strategy. The new year has started well and we are focused on accelerating the momentum built over the last year. We also announce that Derek Hill is stepping down from the Board as an Executive Director today. He will cease to be an employee from 31 March 2018 and will maintain his close relationship with IXICO in a scientific advisory capacity. Derek is a founder of IXICO and has been instrumental in growing the business and transitioning it from a private company to a plc. I have worked with Derek since 2013 and seen the Company grow and develop under his leadership. On behalf of the Board I would like to thank Derek for his hard work and wish him well in his future endeavours.'

For further information please contact:

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available onwww.IXICO.com